絞り込み

16525

広告

Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.

著者 Jacobs A , Kabra R , Das P , Oliphant CS
Future Cardiol.2017 Dec 11 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (62view , 0users)

Full Text Sources

Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.
PMID: 29226697 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード